Topic
Latest reporting and analysis tagged with Eli Lilly.
Nvidia and Eli Lilly announced a $1 billion joint research lab at the JPMorgan Healthcare Conference, aiming to accelerate drug discovery using AI. The five-year project will use Nvidia's latest chips.
Eli Lilly's Taltz and Zepbound show superior efficacy in a Phase 3b trial for psoriatic arthritis and obesity. The company also agreed to acquire Ventyx Biosciences for about $1.2 billion.
Eli Lilly leads the GLP-1 drug market with Mounjaro and Zepbound, but Novo Nordisk's new pill version and high valuation raise investor concerns.